Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1549 to 1550 of 1550 entries
Sorted by: Best Match Show Resources per page
Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes.

Theranostics

Benabdallah N, Scheve W, Dunn N, Silvestros D, Schelker P, Abou D, Jammalamadaka U, Laforest R, Li Z, Liu J, Ballard DH, Maughan NM, Gay H, Baumann BC, Hobbs RF, Rogers B, Iravani A, Jha AK, Dehdashti F, Thorek DLJ.
PMID: 34815780
Theranostics. 2021 Sep 27;11(20):9721-9737. doi: 10.7150/thno.63860. eCollection 2021.

No abstract available.

Cite
Benabdallah N, Scheve W, Dunn N, et al. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics. 2021;11(20):9721-9737doi: 10.7150/thno.63860.
Benabdallah, N., Scheve, W., Dunn, N., Silvestros, D., Schelker, P., Abou, D., Jammalamadaka, U., Laforest, R., Li, Z., Liu, J., Ballard, D. H., Maughan, N. M., Gay, H., Baumann, B. C., Hobbs, R. F., Rogers, B., Iravani, A., Jha, A. K., Dehdashti, F., & Thorek, D. L. J. (2021). Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics, 11(20), 9721-9737. https://doi.org/10.7150/thno.63860
Benabdallah, Nadia, et al. "Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes." Theranostics vol. 11,20 (2021): 9721-9737. doi: https://doi.org/10.7150/thno.63860
Benabdallah N, Scheve W, Dunn N, Silvestros D, Schelker P, Abou D, Jammalamadaka U, Laforest R, Li Z, Liu J, Ballard DH, Maughan NM, Gay H, Baumann BC, Hobbs RF, Rogers B, Iravani A, Jha AK, Dehdashti F, Thorek DLJ. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics. 2021 Sep 27;11(20):9721-9737. doi: 10.7150/thno.63860. eCollection 2021. PMID: 34815780; PMCID: PMC8581409.
Copy Download .nbib Format: NLM
[Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study].

Der Urologe. Ausg. A

Lehmann J, Kluike CW, Haider A, Haider KS, Baumann S, Flesch M, Gedamke M, Kägebein D.
PMID: 34402941
Urologe A. 2021 Aug 17; doi: 10.1007/s00120-021-01620-7. Epub 2021 Aug 17.

BACKGROUND: Androgen deprivation therapy (ADT) with a GnRH agonist or the GnRH antagonist degarelix is a central component in the treatment of prostate cancer (PCa). Little is currently known regarding the decision criteria. Knowledge of these could improve the...

Cite
Lehmann J, Kluike CW, Haider A, et al. Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom : Ergebnisse der ProComD-Studie. [Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study]. Urologe A. 2021;doi: 10.1007/s00120-021-01620-7.
Lehmann, J., Kluike, C. W., Haider, A., Haider, K. S., Baumann, S., Flesch, M., Gedamke, M., & Kägebein, D. (2021). Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom : Ergebnisse der ProComD-Studie. [Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study]. Der Urologe. Ausg. A, . https://doi.org/10.1007/s00120-021-01620-7
Lehmann, J, et al. "Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom : Ergebnisse der ProComD-Studie." [Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study]. Der Urologe. Ausg. A vol. (2021). doi: https://doi.org/10.1007/s00120-021-01620-7
Lehmann J, Kluike CW, Haider A, Haider KS, Baumann S, Flesch M, Gedamke M, Kägebein D. Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom : Ergebnisse der ProComD-Studie. [Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study]. Urologe A. 2021 Aug 17; doi: 10.1007/s00120-021-01620-7. Epub 2021 Aug 17. German. PMID: 34402941.
Copy Download .nbib Format: NLM
Showing 1549 to 1550 of 1550 entries